Current Updates in Management of HER2-Positive and HER2-Low Breast Cancer

AbstractPurpose of ReviewApproximately 1 in 5 breast cancers over-express human epidermal growth factor receptor 2 (HER2). In this review, we discuss the changing landscape of treatments for early and metastatic HER2 breast cancers, new therapies for HER2-low breast cancers, and future investigational directions of HER2-driven disease.Recent FindingsHistorically, HER2 breast cancers have been treated with anti-HER2-targeted therapies in combination with chemotherapy. Recently, clinical trials have established antibody –drug conjugates (ADCs) as an effective additional line of therapy. Previously, patients with HER2-low breast cancers did not derive significant benefit from traditional HER2-directed therapies. However, the treatment paradigm for HER2-low disease has rapidly changed with noted efficacy of fam-tra stuzumab deruxtecan in this population.SummaryIn this review, we outline key historical and recent clinical trials that have shaped HER2 breast cancer management. Active investigation is ongoing to identify and understand mechanisms of resistance.
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research